Inhaled COVID-19 Treatment Advances to Phase 3 Study
Complete the form below to unlock access to ALL audio articles.
The AIDS Clinical Trials Group (ACTG), the largest global HIV research network, which recently expanded its focus to include evaluating outpatient treatment for COVID-19, today announced that the external data and safety monitoring board (DSMB) has recommended that SNG001, an inhaled formulation of interferon beta, advance to phase 3 in the ACTIV-2 Outpatient Monoclonal Antibodies and Other Therapies Trial (ACTG A5401). SNG001 is the third agent to graduate to phase 3 in ACTIV-2, which is evaluating multiple investigational agents to treat early, symptomatic COVID-19 in non-hospitalized individuals. For more information about the trial, please visit the study website.
ACTIV-2 is the first U.S. study to evaluate SNG001 (developed by Synairgen) among non-hospitalized people with COVID-19. SNG001 is self-administered as a nebulized dose (15.6 MIU) that participants inhale once daily for 14 days. Participants are trained to use the nebulizer device by study staff and take all doses at home. BRII-196/BRII-198 (a combination monoclonal antibody treatment) and SAB-185 (a novel polyclonal antibody therapy) are both currently also in phase 3 study in ACTIV-2.
“ACTIV-2 is currently evaluating treatment options that can be delivered in different ways, which is important as we aim to identify solutions that work for people who have a variety of needs,” said ACTG Chair Judith Currier, M.D., M.Sc., University of California, Los Angeles (UCLA). “In addition to a combination monoclonal antibody infusion and polyclonal antibody infusion, this nebulized, inhaled version of interferon beta broadens potential treatment options for people who have COVID-19 but are not hospitalized, which we believe could significantly simplify care for some people with COVID-19.”
The ACTIV-2 DSMB recommended that SNG001 advance into a phase 3 study among participants with mild to moderate COVID-19. The planned phase 3 study will evaluate the safety and efficacy of SNG001 in reducing the risk of hospitalization and death among non-hospitalized adults with COVID-19.
This article has been republished from the following materials. Note: material may have been edited for length and content. For further information, please contact the cited source.